Literature DB >> 6363631

Ganglioside localization on myelinated nerve fibres by cholera toxin binding.

A L Ganser, D A Kirschner, M Willinger.   

Abstract

GM1 ganglioside has been localized on the surfaces of myelinated, peripheral nerve fibres by using immunofluorescence to detect cholera toxin receptors. Unfixed, mouse sciatic nerves were teased into individual, intact fibres in order to expose their extracellular surfaces. Cholera toxin binding sites were abundant at all nodes of Ranvier; they were scarce on the internodal fibre surfaces. The nodal receptors were resistant to various degradative enzymes, including trypsin and proteinase K. Proteases did not unmask receptors on the internodal surfaces. Exogenous GM1 successfully competed for the toxin binding sites on the fibres. From this evidence and the specificity of cholera toxin binding, we conclude that GM1 ganglioside is abundantly present on the membrane surfaces of peripheral nodes of Ranvier and is not present on the internodal Schwann cell surfaces in an appreciable amount. The patterns of fluorescence within the node suggest that the axon and Schwann cell structures are sites where GM1 is localized. Treatment of the teased fibres with Vibrio cholerae neuraminidase, which is known to reduce polysialogangliosides to the monosialoganglioside GM1, induced cholera toxin binding on the internodal Schwann cell surfaces. The induced receptors, as well as their precursors, were resistant to trypsin and proteinase K. We conclude that the internodal Schwann cell surface is rich in an unidentified polysialoganglioside(s) that can be converted to GM1 by neuraminidase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6363631     DOI: 10.1007/bf01153342

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  9 in total

1.  Lumbar dorsal root projections to spinocerebellar cell groups in the rat spinal cord: a double labeling study.

Authors:  C Rivero-Melián; G Grant
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

Review 2.  Gangliosides and glycosphingolipids of peripheral nervous system myelins--a minireview.

Authors:  K Ogawa-Goto; T Abe
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 3.  Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders.

Authors:  P Fredman; A Lekman
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

4.  Choleragenoid horseradish peroxidase used for studying projections of some hindlimb cutaneous nerves and plantar foot afferents to the dorsal horn and Clarke's column in the rat.

Authors:  C Rivero-Melián; G Grant
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

5.  Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier.

Authors:  F P Thomas; W Trojaborg; C Nagy; M Santoro; S A Sadiq; N Latov; A P Hays
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

6.  Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome.

Authors:  D Adams; T Kuntzer; A J Steck; A Lobrinus; R C Janzer; F Regli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

7.  Neuronal cell adhesion molecules and cytotactin are colocalized at the node of Ranvier.

Authors:  F Rieger; J K Daniloff; M Pincon-Raymond; K L Crossin; M Grumet; G M Edelman
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

Review 8.  The role of gangliosides in the organisation of the node of Ranvier examined in glycosyltransferase transgenic mice.

Authors:  Rhona McGonigal; Hugh J Willison
Journal:  J Anat       Date:  2021-10-03       Impact factor: 2.921

Review 9.  MMN: from immunological cross-talk to conduction block.

Authors:  Oliver Harschnitz; Bas A Jongbloed; Hessel Franssen; Dirk C G Straver; W Ludo van der Pol; Leonard H van den Berg
Journal:  J Clin Immunol       Date:  2014-04-13       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.